<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
  <channel>
    <atom:link href="https://feeds.simplecast.com/u1CnkTf7" rel="self" title="MP3 Audio" type="application/atom+xml"/>
    <atom:link href="https://simplecast.superfeedr.com/" rel="hub" xmlns="http://www.w3.org/2005/Atom"/>
    <generator>https://simplecast.com</generator>
    <title>CannaCAST IL</title>
    <description>CannaCAST IL was formed to strengthen and empower the Medical Cannabis industry by providing international exposure to Israel’s technology, R&amp;D and innovation.</description>
    <copyright>CannaCAST IL 2019</copyright>
    <language>en</language>
    <pubDate>Sun, 6 Dec 2020 19:23:48 +0000</pubDate>
    <lastBuildDate>Sun, 6 Dec 2020 19:23:58 +0000</lastBuildDate>
    <image>
      <link>https://cannacast-il.simplecast.com</link>
      <title>CannaCAST IL</title>
      <url>https://image.simplecastcdn.com/images/87cff0ab-cad9-4e7b-9e34-7615b173b9f8/113e9576-0e1c-4cb6-8b2c-feb664054838/3000x3000/cncst_1.jpg?aid=rss_feed</url>
    </image>
    <link>https://cannacast-il.simplecast.com</link>
    <itunes:type>episodic</itunes:type>
    <itunes:summary>CannaCAST IL was formed to strengthen and empower the Medical Cannabis industry by providing international exposure to Israel’s technology, R&amp;D and innovation.</itunes:summary>
    <itunes:author>Heli Dangur, Narkis Tessler</itunes:author>
    <itunes:explicit>yes</itunes:explicit>
    <itunes:image href="https://image.simplecastcdn.com/images/87cff0ab-cad9-4e7b-9e34-7615b173b9f8/113e9576-0e1c-4cb6-8b2c-feb664054838/3000x3000/cncst_1.jpg?aid=rss_feed"/>
    <itunes:new-feed-url>https://feeds.simplecast.com/u1CnkTf7</itunes:new-feed-url>
    <itunes:keywords>#medical cannabis #innovation #israel #medtech</itunes:keywords>
    <itunes:owner>
      <itunes:name>Heli Dangur &amp; Narkis Tessler</itunes:name>
      <itunes:email>cannacast.il@gmail.com</itunes:email>
    </itunes:owner>
    <itunes:category text="Science"/>
    <itunes:category text="Technology"/>
    <itunes:category text="Health &amp; Fitness"/>
    <item>
      <guid isPermaLink="false">94210efd-31e8-482a-96ac-c6184f46975a</guid>
      <title>“The Digital Agronomist – Vision Diagnostics &amp; Remote Plant Scouting for Increased Profits”</title>
      <description>
        <![CDATA[<p>Thank you to our sound editor Daniel Vitas</p>
]]>
      </description>
      <pubDate>Sun, 6 Dec 2020 19:23:48 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/the-digital-agronomist-vision-diagnostics-remote-plant-scouting-for-increased-profits-OH_vmSZW</link>
      <content:encoded>
        <![CDATA[<p>Thank you to our sound editor Daniel Vitas</p>
]]>
      </content:encoded>
      <enclosure length="18953239" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006d5-59c2-45d8-8bb9-69bc8733288d/episodes/c0c35102-3ea4-4029-9ed8-3a22d61dcb83/audio/307d99a9-4ae7-420b-b87f-3fff09f4fc38/default_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“The Digital Agronomist – Vision Diagnostics &amp; Remote Plant Scouting for Increased Profits”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:19:44</itunes:duration>
      <itunes:summary>MyCrops have developed a vision diagnostics platform that uses algorithms, AI &amp; deep learning to remotely identify hot spots of potential plant health issues and to determine optimal plant maturity. Additional platform features provide a significant increase in the bottom line. In today’s CannaCAST IL episode, Assaf Gavish, co-founder, and CSO of MyCrops introduces the platform and its many benefits.

Cultivators interested in learning more about MyCrops, as well as potential investors are invited to reach out to Assaf at: assafg@mycrops.ag , MyCrops website: https://www.mycrops.ag/</itunes:summary>
      <itunes:subtitle>MyCrops have developed a vision diagnostics platform that uses algorithms, AI &amp; deep learning to remotely identify hot spots of potential plant health issues and to determine optimal plant maturity. Additional platform features provide a significant increase in the bottom line. In today’s CannaCAST IL episode, Assaf Gavish, co-founder, and CSO of MyCrops introduces the platform and its many benefits.

Cultivators interested in learning more about MyCrops, as well as potential investors are invited to reach out to Assaf at: assafg@mycrops.ag , MyCrops website: https://www.mycrops.ag/</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>19</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">fe061f3c-9ac8-4d2b-97e7-a894d81081d5</guid>
      <title>“Automation of Home-Grown Medical Grade Cannabis”</title>
      <description>
        <![CDATA[<p>Thanks to our sound editor Daniel Vitas</p>
]]>
      </description>
      <pubDate>Sun, 22 Nov 2020 19:13:17 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/automation-of-home-grown-medical-grade-cannabis-DbaXkyNj</link>
      <content:encoded>
        <![CDATA[<p>Thanks to our sound editor Daniel Vitas</p>
]]>
      </content:encoded>
      <enclosure length="15695247" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006d5-59c2-45d8-8bb9-69bc8733288d/episodes/54ee8f99-db9a-4548-9d9e-76588f82b08d/audio/aa90f15a-94c5-4de1-88d6-5626b8aab119/default_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Automation of Home-Grown Medical Grade Cannabis”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:16:20</itunes:duration>
      <itunes:summary>Grow Director, led by Dima Chernobilsky, Co-Founder &amp; CEO, have simplified and automated the process of growing medical grade cannabis to enable consistent growing of your optimal growth protocol, with minimal intervention so that you can start the system and come back only when the entire growth cycle is complete. Grow Director’s platform also includes a community feature that enables home-growers to share their protocols and knowledge.
Potential distributors who are cannabis insiders in their markets, as well as potential investors are invited to reach out to Dima at: dima@growdirector.com , Grow Director website: https://growdirector.com/
</itunes:summary>
      <itunes:subtitle>Grow Director, led by Dima Chernobilsky, Co-Founder &amp; CEO, have simplified and automated the process of growing medical grade cannabis to enable consistent growing of your optimal growth protocol, with minimal intervention so that you can start the system and come back only when the entire growth cycle is complete. Grow Director’s platform also includes a community feature that enables home-growers to share their protocols and knowledge.
Potential distributors who are cannabis insiders in their markets, as well as potential investors are invited to reach out to Dima at: dima@growdirector.com , Grow Director website: https://growdirector.com/
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>18</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bce5a655-4741-4a46-9c24-7742285f002f</guid>
      <title>“Cannabis On-Site Potency Testing in Under 5 Minutes”</title>
      <description>
        <![CDATA[<p>Thank you to our sound editor Daniel Vitas</p>
]]>
      </description>
      <pubDate>Mon, 26 Oct 2020 18:39:45 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/cannabis-on-site-potency-testing-in-under-5-minutes-s3_euucL</link>
      <content:encoded>
        <![CDATA[<p>Thank you to our sound editor Daniel Vitas</p>
]]>
      </content:encoded>
      <enclosure length="20624239" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006d5-59c2-45d8-8bb9-69bc8733288d/episodes/7027e6e6-2221-4887-b6bd-a5ebcc2719f9/audio/6bc1cf70-16b0-4de3-a62e-46e61d3c07d1/default_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Cannabis On-Site Potency Testing in Under 5 Minutes”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:21:28</itunes:duration>
      <itunes:summary>GemmaCert, led by Guy Setton, PhD., Co-Founder &amp; CEO, has disrupted the cannabis testing industry with a portable, user-friendly &amp; affordable device for testing cannabis potency that provides results in under 5 minutes. GemmaCert devices have been sold in 30 countries on 6 continents – setting the standard for diagnostic on-site solutions. Guy offers us insights into the key success factors that enabled their success.

Potential distributors who are cannabis insiders in their markets, as well as potential investors are invited to reach out to Guy at guy.setton@gmail.com, GemmaCert website: https://gemmacert.com/
</itunes:summary>
      <itunes:subtitle>GemmaCert, led by Guy Setton, PhD., Co-Founder &amp; CEO, has disrupted the cannabis testing industry with a portable, user-friendly &amp; affordable device for testing cannabis potency that provides results in under 5 minutes. GemmaCert devices have been sold in 30 countries on 6 continents – setting the standard for diagnostic on-site solutions. Guy offers us insights into the key success factors that enabled their success.

Potential distributors who are cannabis insiders in their markets, as well as potential investors are invited to reach out to Guy at guy.setton@gmail.com, GemmaCert website: https://gemmacert.com/
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>17</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">533b665d-2f06-499c-ac29-d3f62e7d0b8d</guid>
      <title>“Personalized Sublingual Delivery”</title>
      <description>
        <![CDATA[<p>Thanks to our sound editor Daniel Vitas.</p>
]]>
      </description>
      <pubDate>Sun, 11 Oct 2020 17:34:00 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/personalized-sublingual-delivery-A2ShbmBG</link>
      <content:encoded>
        <![CDATA[<p>Thanks to our sound editor Daniel Vitas.</p>
]]>
      </content:encoded>
      <enclosure length="15539348" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006d5-59c2-45d8-8bb9-69bc8733288d/episodes/72617baf-2edc-4b5c-bb61-f73b758db04a/audio/1296cc69-868c-41ce-939b-63d959c726ec/default_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Personalized Sublingual Delivery”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:16:10</itunes:duration>
      <itunes:summary>Today we host Yaron Shoob, Founder and CEO of Elixie SL. Yaron and his team have solved the challenges of both rapid onset and high bioavailability without smoking or vaping – Elixie SL’s Personalized Sublingual Delivery System. The Elixie SL device utilizes a dynamic release mechanism in which the rate of release is determined by the individual’s personal anatomy. 
Potential investors or strategic partners looking to collaborate are invited to reach out to Yaron at: yaron@elixie.tech, Elixie SL website: https://www.elixie.tech/

</itunes:summary>
      <itunes:subtitle>Today we host Yaron Shoob, Founder and CEO of Elixie SL. Yaron and his team have solved the challenges of both rapid onset and high bioavailability without smoking or vaping – Elixie SL’s Personalized Sublingual Delivery System. The Elixie SL device utilizes a dynamic release mechanism in which the rate of release is determined by the individual’s personal anatomy. 
Potential investors or strategic partners looking to collaborate are invited to reach out to Yaron at: yaron@elixie.tech, Elixie SL website: https://www.elixie.tech/

</itunes:subtitle>
      <itunes:keywords>delivery system, cannabis inoovation, medical cannabis, medical device</itunes:keywords>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>16</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c9e267d6-406b-418f-ba40-f14319c62ee3</guid>
      <title>“Personalization Technology, Medicinal Mushrooms &amp; Cannabinoids”</title>
      <description>
        <![CDATA[<p>Thank you to our sound editor Guy Ben Gad</p>
]]>
      </description>
      <pubDate>Mon, 24 Aug 2020 17:01:12 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/personalization-technology-medicinal-mushrooms-cannabinoids-6vJZzPBS</link>
      <content:encoded>
        <![CDATA[<p>Thank you to our sound editor Guy Ben Gad</p>
]]>
      </content:encoded>
      <enclosure length="23560041" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/46b74ac5-9b31-4c3c-ae01-1857e50bc964/cannabotech-mp3-2_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Personalization Technology, Medicinal Mushrooms &amp; Cannabinoids”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:24:32</itunes:duration>
      <itunes:summary>Today we interviewed Moav Gafni, Co-founder and Business Development Manager of Cannabotech, a biopharmaceutical company with a focus on the prevention and treatment of cancer, chronic pain and inflammation using botanical elements from medicinal mushrooms and cannabinoids.
Everything about Cannabotech is innovative – their wellness products, their personalization technology, their pharmaceutical formulas, and wearable medical device, and even their capital-raising strategy!
Moav invites potential strategic partners, research collaboration partners, distributors, and potential investors to reach out at Moav@Cannabotech.com    Cannabotech website:  https://www.cannabotech.com/
</itunes:summary>
      <itunes:subtitle>Today we interviewed Moav Gafni, Co-founder and Business Development Manager of Cannabotech, a biopharmaceutical company with a focus on the prevention and treatment of cancer, chronic pain and inflammation using botanical elements from medicinal mushrooms and cannabinoids.
Everything about Cannabotech is innovative – their wellness products, their personalization technology, their pharmaceutical formulas, and wearable medical device, and even their capital-raising strategy!
Moav invites potential strategic partners, research collaboration partners, distributors, and potential investors to reach out at Moav@Cannabotech.com    Cannabotech website:  https://www.cannabotech.com/
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>15</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">a5b2cb65-20ee-4a16-8201-9ecd89e89157</guid>
      <title>“Bio-Reactors &amp; Pharma-Grade Full Spectrum Cannabis”</title>
      <description>
        <![CDATA[<p>Thank you to our sound editor Guy Ben Gad.</p>
]]>
      </description>
      <pubDate>Sun, 16 Aug 2020 17:25:45 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/bio-reactors-pharma-grade-full-spectrum-cannabis-ciyxzJda</link>
      <content:encoded>
        <![CDATA[<p>Thank you to our sound editor Guy Ben Gad.</p>
]]>
      </content:encoded>
      <enclosure length="11503952" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/a708066d-779a-4685-84b2-d22d3c39dfed/cannadorf-pro-mixdown_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Bio-Reactors &amp; Pharma-Grade Full Spectrum Cannabis”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:11:59</itunes:duration>
      <itunes:summary>Today we host Dr. Kobi Buxdorf, Founder and CEO of Cannadorf. Kobi reveals to us how Cannadorf is able to sidestep all growing obstacles and manufacture cannabis in a closed biological environment to produce sterile, all-natural, full-spectrum pharma-grade cannabis, with consistently identical profiles every single time. 

Potential pharma companies or cannabis-based drug developers looking to collaborate are invited to reach out to Kobi at kobi@cannadorf.com, Cannadorf website: https://cannadorf.com/</itunes:summary>
      <itunes:subtitle>Today we host Dr. Kobi Buxdorf, Founder and CEO of Cannadorf. Kobi reveals to us how Cannadorf is able to sidestep all growing obstacles and manufacture cannabis in a closed biological environment to produce sterile, all-natural, full-spectrum pharma-grade cannabis, with consistently identical profiles every single time. 

Potential pharma companies or cannabis-based drug developers looking to collaborate are invited to reach out to Kobi at kobi@cannadorf.com, Cannadorf website: https://cannadorf.com/</itunes:subtitle>
      <itunes:keywords>cannabis</itunes:keywords>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>14</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c5c2aade-2ce1-4d6f-aa59-76bcfd3c1743</guid>
      <title>“Medicalizing Vaporization”</title>
      <description>In today’s podcast, we interview Avihu Tamir, Founder, and CEO of Kanabo Research. Kanabo has developed an innovative medical-grade vaporization device that provides metered doses at a standard of safety and quality that physicians can trust. 
The vaporization device uses only 100% pure extracted pharmaceutical-grade cannabis with no added carriers or additives, with formulations targeted at specific medical indications. 
Potential distributors, as well as research partners looking to perform clinical trials using Kanabo’s platform, are invited to reach out at avihu@kanaboresearch.com   Kanabo website: https://www.kanabogroup.com/

</description>
      <pubDate>Tue, 4 Aug 2020 17:19:12 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/medicalizing-vaporization-Fm1_u8dS</link>
      <enclosure length="16056226" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/dc6fca42-8160-4a89-9c38-5871955aaa39/episode-kannbo-mixdown-with-music-fix_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Medicalizing Vaporization”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:16:44</itunes:duration>
      <itunes:summary>In today’s podcast, we interview Avihu Tamir, Founder, and CEO of Kanabo Research. Kanabo has developed an innovative medical-grade vaporization device that provides metered doses at a standard of safety and quality that physicians can trust. 
The vaporization device uses only 100% pure extracted pharmaceutical-grade cannabis with no added carriers or additives, with formulations targeted at specific medical indications. 
Potential distributors, as well as research partners looking to perform clinical trials using Kanabo’s platform, are invited to reach out at avihu@kanaboresearch.com   Kanabo website: https://www.kanabogroup.com/

</itunes:summary>
      <itunes:subtitle>In today’s podcast, we interview Avihu Tamir, Founder, and CEO of Kanabo Research. Kanabo has developed an innovative medical-grade vaporization device that provides metered doses at a standard of safety and quality that physicians can trust. 
The vaporization device uses only 100% pure extracted pharmaceutical-grade cannabis with no added carriers or additives, with formulations targeted at specific medical indications. 
Potential distributors, as well as research partners looking to perform clinical trials using Kanabo’s platform, are invited to reach out at avihu@kanaboresearch.com   Kanabo website: https://www.kanabogroup.com/

</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>13</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c6b1cf77-54da-4f62-99ac-0e0cd628390e</guid>
      <title>"Obesity, Diabetes, Weight Loss and Cannabinoids"</title>
      <description>
        <![CDATA[<p>Special thanks to Ehud Yerushalmi, our sound editor.</p>
]]>
      </description>
      <pubDate>Sun, 26 Jul 2020 05:13:24 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/obesity-diabetes-weight-loss-and-cannabinoids-sA4FfSSu</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Ehud Yerushalmi, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="16243245" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/6b8e6ca8-4eae-45fc-89d6-bee9a7ab1ecb/citech-mix-01_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>"Obesity, Diabetes, Weight Loss and Cannabinoids"</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:16:55</itunes:duration>
      <itunes:summary>In this episode, Clifton Flack, founder, and CEO of CiiTech, reveals a revolutionary approach to weight loss that’s not centered around appetite suppression. CiiTech is conducting research centered around Fatty Liver Disease, Obesity, and Diabetes. Once patent approval is attained, Ciitech will launch a food supplement version of their unique cannabinoid formulation, while continuing the clinical studies to complete and launch a pharma version of the treatment. Learn about their unique approach and two-pronged mechanism in today’s podcast.  
Interestingly, though CiiTech currently sells and distributes its line of food supplements in the UK, Clifton has chosen to conduct the research and clinical studies in Israel. In his words: “in addition to Israel’s vast data &amp; experience in medical cannabis research and Israel’s medical innovation mentality, costs of the entire process are significantly more attractive in Israel.”
POTENTIAL GLOBAL DISTRIBUTORS interested in distributing the food supplement version, 
as well as SMART INVESTORS that can add value to the pharma solution are invited to reach out to Clifton at: 
clifton@ciitech.co.uk 
https://ciitech.co.il/

</itunes:summary>
      <itunes:subtitle>In this episode, Clifton Flack, founder, and CEO of CiiTech, reveals a revolutionary approach to weight loss that’s not centered around appetite suppression. CiiTech is conducting research centered around Fatty Liver Disease, Obesity, and Diabetes. Once patent approval is attained, Ciitech will launch a food supplement version of their unique cannabinoid formulation, while continuing the clinical studies to complete and launch a pharma version of the treatment. Learn about their unique approach and two-pronged mechanism in today’s podcast.  
Interestingly, though CiiTech currently sells and distributes its line of food supplements in the UK, Clifton has chosen to conduct the research and clinical studies in Israel. In his words: “in addition to Israel’s vast data &amp; experience in medical cannabis research and Israel’s medical innovation mentality, costs of the entire process are significantly more attractive in Israel.”
POTENTIAL GLOBAL DISTRIBUTORS interested in distributing the food supplement version, 
as well as SMART INVESTORS that can add value to the pharma solution are invited to reach out to Clifton at: 
clifton@ciitech.co.uk 
https://ciitech.co.il/

</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>12</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">96c9ef18-cfb9-436b-88da-4a21a24dc8c7</guid>
      <title>"Nanotechnology and the Blood Brain Barrier"</title>
      <description>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </description>
      <pubDate>Sun, 19 Jul 2020 13:47:28 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/nanotechnology-and-the-blood-brain-barrier-opeam9gI</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="19869216" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/77b8fe9a-22b4-463e-a434-662152723be7/cannacast-nextage-orna_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>"Nanotechnology and the Blood Brain Barrier"</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:20:42</itunes:duration>
      <itunes:summary>In this episode, Dr. Orna Dreazen, chairperson of Nextage Cannabis Innovations and Nextar ChemPharma Solutions tells us about breakthrough developments coming out of Nextage.
Nextage has developed nanotechnology that enables the penetration of various drugs, including cannabinoids, into the blood brain barrier, exhibiting both safety and efficacy.
Dr. Dreazen also describes exciting developments with some of the rare cannabinoids such as CBN.
Investors, as well as potential licensing partners, are welcome to reach out to Dr. Dreazen at
OrnaD@Nextar.co.il
Nextage Cannabis Innovation Center https://nextageinnovation.com/
Nextar ChemPharma Solutions https://www.nextar.co.il/
</itunes:summary>
      <itunes:subtitle>In this episode, Dr. Orna Dreazen, chairperson of Nextage Cannabis Innovations and Nextar ChemPharma Solutions tells us about breakthrough developments coming out of Nextage.
Nextage has developed nanotechnology that enables the penetration of various drugs, including cannabinoids, into the blood brain barrier, exhibiting both safety and efficacy.
Dr. Dreazen also describes exciting developments with some of the rare cannabinoids such as CBN.
Investors, as well as potential licensing partners, are welcome to reach out to Dr. Dreazen at
OrnaD@Nextar.co.il
Nextage Cannabis Innovation Center https://nextageinnovation.com/
Nextar ChemPharma Solutions https://www.nextar.co.il/
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>11</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5e37a693-db3d-4597-820b-e3ec93bfe43e</guid>
      <title>“Decoding Biology to Identify New Genetics in Cannabis”</title>
      <description>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </description>
      <pubDate>Mon, 13 Jul 2020 14:32:02 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/decoding-biology-to-identify-new-genetics-in-cannabis-5mgxEJGx</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="11430804" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/c0831d26-5136-4876-8a3c-738bed3de5e8/cannacastil-canonic-arnon-after-cuts_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“Decoding Biology to Identify New Genetics in Cannabis”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:11:54</itunes:duration>
      <itunes:summary>In our new episode, we spoke with Dr. Arnon Heyman, PhD in Plant Biotechnology and CEO of Canonic, a subsidiary of Evogene. Canonic brings new genetics to the cannabis market using a Computational Predictive Biology (CPB) platform which enables them to use Big Data and AI to reach insights within the plant genetics for specific medical indications. Arnon recommends addressing three key industry pains: genetic stability, compound yield and active compounds via the plant genetics. 
Canonic is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), the company’s strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical Cannabis products. 
Investors, distributors or growers interested in collaboration are invited to reach Arnon are invited at: 
arnon.heyman@canonicbio.com  
Canonic’s website: www.canonicbio.com
 
</itunes:summary>
      <itunes:subtitle>In our new episode, we spoke with Dr. Arnon Heyman, PhD in Plant Biotechnology and CEO of Canonic, a subsidiary of Evogene. Canonic brings new genetics to the cannabis market using a Computational Predictive Biology (CPB) platform which enables them to use Big Data and AI to reach insights within the plant genetics for specific medical indications. Arnon recommends addressing three key industry pains: genetic stability, compound yield and active compounds via the plant genetics. 
Canonic is a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), the company’s strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations. Canonic has exclusive access to Evogene’s genomic assets and technology for the development of medical Cannabis products. 
Investors, distributors or growers interested in collaboration are invited to reach Arnon are invited at: 
arnon.heyman@canonicbio.com  
Canonic’s website: www.canonicbio.com
 
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>10</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">590b3b44-b25f-44f2-9f30-27ad4408716d</guid>
      <title>“1 CBD-based patent - 130 potential medical indications”</title>
      <description>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </description>
      <pubDate>Wed, 17 Jun 2020 03:11:45 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/1-cbd-based-patent-130-potential-medical-indications-Gfxxav4G</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="15383547" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/e4ba7002-58da-4c0f-a53e-9464a46402e4/cannacastil-david-after-cut-4_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>“1 CBD-based patent - 130 potential medical indications”</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:16:01</itunes:duration>
      <itunes:summary>In today’s episode, we host David Bassa, a serial entrepreneur for the past 30 years in the fields of hi-tech and biotech, with an emphasis on cannabis-based pharma. His company, Stero Biotechs has been issued a CBD-based patent covering over 130 different indications. Stero Biotechs is currently conducting seven different research studies for 7 different indications, two of them in clinical trials (Chron’s disease and Urticaria, also known as hives). Stero Biotechs’s research combats the side effects of steroids, often decreasing or even eliminating steroid use while treating the relevant medical indications.
Stero Biotech is an excellent example of Israel’s leading edge in developing Pharma based products, with Israel’s leading HMO as a shareholder, providing access to 5 million patients, 9000 physicians,  14 hospitals and significant cost-efficiency in conducting clinical trials. 

Stero Biotechs welcomes strategic collaboration opportunities, contact them through: http://sterobiotechs.com or guyd@sela.co.il</itunes:summary>
      <itunes:subtitle>In today’s episode, we host David Bassa, a serial entrepreneur for the past 30 years in the fields of hi-tech and biotech, with an emphasis on cannabis-based pharma. His company, Stero Biotechs has been issued a CBD-based patent covering over 130 different indications. Stero Biotechs is currently conducting seven different research studies for 7 different indications, two of them in clinical trials (Chron’s disease and Urticaria, also known as hives). Stero Biotechs’s research combats the side effects of steroids, often decreasing or even eliminating steroid use while treating the relevant medical indications.
Stero Biotech is an excellent example of Israel’s leading edge in developing Pharma based products, with Israel’s leading HMO as a shareholder, providing access to 5 million patients, 9000 physicians,  14 hospitals and significant cost-efficiency in conducting clinical trials. 

Stero Biotechs welcomes strategic collaboration opportunities, contact them through: http://sterobiotechs.com or guyd@sela.co.il</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>9</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c3495b4a-fa41-4b6d-83a8-88d59ad809e5</guid>
      <title>”It’s all about molecules”- innovative pharma products</title>
      <description>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </description>
      <pubDate>Wed, 3 Jun 2020 04:35:18 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/its-all-about-molecules-innovative-pharma-products-J6nr2i5y</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="14996154" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/6f6b3847-9e2b-496a-8738-bac0ec039112/canncast-il-nir-new-edit_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>”It’s all about molecules”- innovative pharma products</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:15:37</itunes:duration>
      <itunes:summary>In this episode, we host Nir Peles, Founder, BOD member and VP Business Development at Cannassure Therapeutics to discuss Cannassure’s cannabis-based pharma products.
Cannassure is currently developing innovative &amp; standardized IP protected pharma products with the ‘look and feel’ of pharma products as opposed to plants. These products address topical delivery for skin indications such as psoriasis and rheumatism, fem-tech IUD targeting women’s health issues, and a standardized pill for delivering medical cannabis.
One of Israel’s leading cannabis producers, Cannassure produces medical-grade cannabis in a holistic integrated production system that includes an advanced indoor-aeroponic grow facility, a state-of-the-art extraction and processing facility, together with scientifically advanced R&amp;D.
Nir welcomes strategic collaboration opportunities, contact him through his LinkedIn profile
Cannassure is publicly traded -  TASE: CSURE, 
Visit their website: http://cannassure.life/ 
</itunes:summary>
      <itunes:subtitle>In this episode, we host Nir Peles, Founder, BOD member and VP Business Development at Cannassure Therapeutics to discuss Cannassure’s cannabis-based pharma products.
Cannassure is currently developing innovative &amp; standardized IP protected pharma products with the ‘look and feel’ of pharma products as opposed to plants. These products address topical delivery for skin indications such as psoriasis and rheumatism, fem-tech IUD targeting women’s health issues, and a standardized pill for delivering medical cannabis.
One of Israel’s leading cannabis producers, Cannassure produces medical-grade cannabis in a holistic integrated production system that includes an advanced indoor-aeroponic grow facility, a state-of-the-art extraction and processing facility, together with scientifically advanced R&amp;D.
Nir welcomes strategic collaboration opportunities, contact him through his LinkedIn profile
Cannassure is publicly traded -  TASE: CSURE, 
Visit their website: http://cannassure.life/ 
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>8</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f12d6f5a-fcef-43bc-ac00-4a6bcb53134d</guid>
      <title>The Molecular Method for discovering APIs for specific medical indications</title>
      <description>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </description>
      <pubDate>Mon, 18 May 2020 14:08:37 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/the-molecular-method-for-discovering-apis-for-specific-medical-indications-2KfqhRq4</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="10324920" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/a24da0bf-419c-45ef-864d-c1fda2661aa6/canncast-il-hinanit-new_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>The Molecular Method for discovering APIs for specific medical indications</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:10:45</itunes:duration>
      <itunes:summary>In this episode, we host Prof. Hinanit Koltai of Israel’s Volcan Research Institute to discuss innovation in molecular plant science. Prof. Koltai walks us through the Volcan Institute’s molecular method for discovering the specific combinations of cannabis compounds beneficial in the treatment of medical indications such as inflammatory bowel disease, skin cancer, and colon cancer. Results of the research on skin cancer were recently published in Oncotarget https://www.oncotarget.com/article/27528/text/
Prof. Koltai’s research team begins with the Volcan Institute's extensive gene bank of cannabis strains from around the world and culminates in clinical trials performed in collaboration with Israel’s physicians and hospitals to validate APIs for each specific medical indication.
To collaborate with Prof. Koltai’s research team – contact Hinanit at hkoltai@volcani.agri.gov.il
</itunes:summary>
      <itunes:subtitle>In this episode, we host Prof. Hinanit Koltai of Israel’s Volcan Research Institute to discuss innovation in molecular plant science. Prof. Koltai walks us through the Volcan Institute’s molecular method for discovering the specific combinations of cannabis compounds beneficial in the treatment of medical indications such as inflammatory bowel disease, skin cancer, and colon cancer. Results of the research on skin cancer were recently published in Oncotarget https://www.oncotarget.com/article/27528/text/
Prof. Koltai’s research team begins with the Volcan Institute's extensive gene bank of cannabis strains from around the world and culminates in clinical trials performed in collaboration with Israel’s physicians and hospitals to validate APIs for each specific medical indication.
To collaborate with Prof. Koltai’s research team – contact Hinanit at hkoltai@volcani.agri.gov.il
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>7</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">53a29d9b-ac23-47f7-9285-89daa948e669</guid>
      <title>COVID-19 - A revolutionary treatment approach!</title>
      <description>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </description>
      <pubDate>Mon, 18 May 2020 14:04:33 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/covid-19-a-revolutionary-treatment-approach-llC75cU3</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Maor Asher, our sound editor.</p>
]]>
      </content:encoded>
      <enclosure length="16032399" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/67b9d807-694d-42a9-a6da-d0450b74349c/canncast-il-iris-new-time_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>COVID-19 - A revolutionary treatment approach!</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:16:42</itunes:duration>
      <itunes:summary>In this episode, Iris Bincovich, CEO of Innocan Pharma shares Innocan’s collaboration with Tel Aviv University to develop a novel, revolutionary approach to treat COVID-19 by using CBD loaded Exosomes. In addition to treating COVID-19, the new drug will target additional central nervous system indications. The goal is to be ready in 2021 to conduct a licensing agreement with a large pharma company.
Additionally, Iris shared that Innocan will be launching their new line of CBD topicals, produced in Portugal and the US, during Q2 of this year, including a line of “relief and go” pain-relief topicals as well as a line of cosmetic products.
Interested in being a distributor? Contact:  irisb@innocanpharma.com
</itunes:summary>
      <itunes:subtitle>In this episode, Iris Bincovich, CEO of Innocan Pharma shares Innocan’s collaboration with Tel Aviv University to develop a novel, revolutionary approach to treat COVID-19 by using CBD loaded Exosomes. In addition to treating COVID-19, the new drug will target additional central nervous system indications. The goal is to be ready in 2021 to conduct a licensing agreement with a large pharma company.
Additionally, Iris shared that Innocan will be launching their new line of CBD topicals, produced in Portugal and the US, during Q2 of this year, including a line of “relief and go” pain-relief topicals as well as a line of cosmetic products.
Interested in being a distributor? Contact:  irisb@innocanpharma.com
</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>6</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">68a46077-d059-4245-a83b-63f3527f9cd0</guid>
      <title>Breakthrough in Cannabis aid for Endometriosis</title>
      <description>
        <![CDATA[<p>Special thanks to Amit Bagam, our sound editor, and to Google Studios for the use of their state-of-the-art recording studio.</p>
]]>
      </description>
      <pubDate>Thu, 26 Mar 2020 16:10:01 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/episode-5gynica-iQ7qw5BM</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Amit Bagam, our sound editor, and to Google Studios for the use of their state-of-the-art recording studio.</p>
]]>
      </content:encoded>
      <enclosure length="12712335" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/2571b904-e0c8-430b-b262-5c3b9aea72f2/yotam-final-cut-new_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>Breakthrough in Cannabis aid for Endometriosis</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:13:14</itunes:duration>
      <itunes:summary>In this episode, we focus on Cannabis and women’s health with Yotam Hod, CEO &amp; Co-Founder of Lumir Labs, Gynica and Asana Bio Group. 
Yotam shares with us an exciting breakthrough in the field of endometriosis . Gynica is currently looking for global partners for licensing their evidence-based products: yotam@gynica.com</itunes:summary>
      <itunes:subtitle>In this episode, we focus on Cannabis and women’s health with Yotam Hod, CEO &amp; Co-Founder of Lumir Labs, Gynica and Asana Bio Group. 
Yotam shares with us an exciting breakthrough in the field of endometriosis . Gynica is currently looking for global partners for licensing their evidence-based products: yotam@gynica.com</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>5</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">8b3a44db-2b9d-4fd5-81c4-38596d725578</guid>
      <title>What's Israel's leading edge in the cannabis industry in 2020?</title>
      <description>
        <![CDATA[<p>Special thanks to Amit Begam, our sound editor, and to Google Studios for the use of their state-of-the-art recording studio.</p>
]]>
      </description>
      <pubDate>Wed, 18 Mar 2020 14:03:55 +0000</pubDate>
      <author>cannacast.il@gmail.com (Heli Dangur &amp; Narkis Tessler)</author>
      <link>https://cannacast-il.simplecast.com/episodes/episode-4-W8qT6_TW</link>
      <content:encoded>
        <![CDATA[<p>Special thanks to Amit Begam, our sound editor, and to Google Studios for the use of their state-of-the-art recording studio.</p>
]]>
      </content:encoded>
      <enclosure length="32736279" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/e66787d7-2e9e-4433-be59-779b658539e3/cannacast-il-nadav-final_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>What's Israel's leading edge in the cannabis industry in 2020?</itunes:title>
      <itunes:author>Heli Dangur &amp; Narkis Tessler</itunes:author>
      <itunes:duration>00:34:04</itunes:duration>
      <itunes:summary>We’re excited to return to broadcasting with this episode with Nadav Gil, Partner at Deloitte Israel and leader of the Israeli Cannabis Practice.

In our discussion, Nadav presents an overview of the opportunities the Israeli cannabis researchers and companies offer to the global cannabis market in 2020 and describes Israel’s leading edge in science and technology.</itunes:summary>
      <itunes:subtitle>We’re excited to return to broadcasting with this episode with Nadav Gil, Partner at Deloitte Israel and leader of the Israeli Cannabis Practice.

In our discussion, Nadav presents an overview of the opportunities the Israeli cannabis researchers and companies offer to the global cannabis market in 2020 and describes Israel’s leading edge in science and technology.</itunes:subtitle>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>4</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">36f3ac37-30ec-4b2a-a569-2828918f7c41</guid>
      <title>Innovation in Cannabis Medicine</title>
      <description>In this week's CANNACAST IL episode - "Innovation in Cannabis Medicine" - we speak to two start-ups. Our first guest, Prof. Nissim Garti of LDS technologies, has developed breakthrough Lyotropic Delivery Systems.  Our second guest, Dr. Haleli Sharir of Cannabics Pharmaceuticals, is developing Personalized Cannabinoid Medication.</description>
      <pubDate>Tue, 20 Aug 2019 05:56:18 +0000</pubDate>
      <author>cannacast.il@gmail.com (Google for Entrepreneurs- Creators studio ; Doron Gozal Goldschmidt - Sound Editor)</author>
      <link>https://cannacast-il.simplecast.com/episodes/innovation-in-cannabis-medicine-2t8rmu4h</link>
      <enclosure length="14266800" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/ce0e377e-15f8-46d2-9803-b0e65eca829f/ep_3_v2_01_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>Innovation in Cannabis Medicine</itunes:title>
      <itunes:author>Google for Entrepreneurs- Creators studio ; Doron Gozal Goldschmidt - Sound Editor</itunes:author>
      <itunes:duration>00:14:52</itunes:duration>
      <itunes:summary>In this week's CANNACAST IL episode - "Innovation in Cannabis Medicine" - we speak to two start-ups. Our first guest, Prof. Nissim Garti of LDS technologies, has developed breakthrough Lyotropic Delivery Systems.  Our second guest, Dr. Haleli Sharir of Cannabics Pharmaceuticals, is developing Personalized Cannabinoid Medication.</itunes:summary>
      <itunes:subtitle>In this week's CANNACAST IL episode - "Innovation in Cannabis Medicine" - we speak to two start-ups. Our first guest, Prof. Nissim Garti of LDS technologies, has developed breakthrough Lyotropic Delivery Systems.  Our second guest, Dr. Haleli Sharir of Cannabics Pharmaceuticals, is developing Personalized Cannabinoid Medication.</itunes:subtitle>
      <itunes:keywords>personalize medicine, cannabis medicine; pharma;health;delivery systems;pharmaceuticals</itunes:keywords>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>3</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">6a7e84ed-bb64-4897-9e4f-bb99158f53c5</guid>
      <title>Professor Raphael Mechoulam- INNOVATION in CLINICAL RESEARCH &amp; CLINICAL TRIALS</title>
      <description>Professor Raphael Mechoulam, Israel’s world-renowned cannabis researcher, in an open discussion regarding today’s clinical research needs and challenges.</description>
      <pubDate>Mon, 12 Aug 2019 14:59:12 +0000</pubDate>
      <author>cannacast.il@gmail.com (Google for Entrepreneurs- Creators studio  ; Doron Gozal Goldschmidt - Sound Editor)</author>
      <link>https://cannacast-il.simplecast.com/episodes/professor-raphael-mechoulam-innovation-in-clinical-research-clinical-trials-uTRWBNnw</link>
      <enclosure length="26098807" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/f18c0441-9606-48e4-aafa-31d6881c8820/ep_2_meshulam_v2_01_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>Professor Raphael Mechoulam- INNOVATION in CLINICAL RESEARCH &amp; CLINICAL TRIALS</itunes:title>
      <itunes:author>Google for Entrepreneurs- Creators studio  ; Doron Gozal Goldschmidt - Sound Editor</itunes:author>
      <itunes:duration>00:27:11</itunes:duration>
      <itunes:summary>Professor Raphael Mechoulam, Israel’s world-renowned cannabis researcher, in an open discussion regarding today’s clinical research needs and challenges.</itunes:summary>
      <itunes:subtitle>Professor Raphael Mechoulam, Israel’s world-renowned cannabis researcher, in an open discussion regarding today’s clinical research needs and challenges.</itunes:subtitle>
      <itunes:keywords>professor raphael mechoulam, clinical research, israel clinical trials, medical cannabis</itunes:keywords>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>2</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">e20d5e0a-2f5a-456a-badf-82bbcb5921e0</guid>
      <title>CannaCAST IL Introduction</title>
      <description>CannaCAST IL was formed to strengthen and empower the Medical Cannabis industry by providing international exposure to Israel’s technology, R&amp;D and innovation. 
Meet the Podcast Moderators :
Heli Dangur, Director of Global Business Development, Cann10
Narkis Tessler, CEO at TeraCann and managing partner at Blue Pesto</description>
      <pubDate>Mon, 12 Aug 2019 14:26:48 +0000</pubDate>
      <author>cannacast.il@gmail.com (Google for Entrepreneurs- Creators studio, Doron Gozal Goldschmidt - Sound Editor)</author>
      <link>https://cannacast-il.simplecast.com/episodes/cannacast-il-introduction-YgEDLkM1</link>
      <enclosure length="8384025" type="audio/mpeg" url="https://cdn.simplecast.com/audio/ead006/ead006d5-59c2-45d8-8bb9-69bc8733288d/5aeedce8-bdee-4ea1-8a45-bde876e9f503/ep1_complete_v2_01_tc.mp3?aid=rss_feed&amp;feed=u1CnkTf7"/>
      <itunes:title>CannaCAST IL Introduction</itunes:title>
      <itunes:author>Google for Entrepreneurs- Creators studio, Doron Gozal Goldschmidt - Sound Editor</itunes:author>
      <itunes:duration>00:08:44</itunes:duration>
      <itunes:summary>CannaCAST IL was formed to strengthen and empower the Medical Cannabis industry by providing international exposure to Israel’s technology, R&amp;D and innovation. 
Meet the Podcast Moderators :
Heli Dangur, Director of Global Business Development, Cann10
Narkis Tessler, CEO at TeraCann and managing partner at Blue Pesto</itunes:summary>
      <itunes:subtitle>CannaCAST IL was formed to strengthen and empower the Medical Cannabis industry by providing international exposure to Israel’s technology, R&amp;D and innovation. 
Meet the Podcast Moderators :
Heli Dangur, Director of Global Business Development, Cann10
Narkis Tessler, CEO at TeraCann and managing partner at Blue Pesto</itunes:subtitle>
      <itunes:keywords>cannacast il, cannabis technology, israel innovation, cannabis innovation, medical cannabis</itunes:keywords>
      <itunes:explicit>yes</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>1</itunes:episode>
    </item>
  </channel>
</rss>